DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
47 hedge funds and large institutions have $2.74M invested in DMK Pharmaceuticals Corporation Common Stock in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
0% more funds holding
Funds holding: 47 → 47 (0)
53% less capital invested
Capital invested by funds: $5.8M → $2.74M (-$3.06M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$41.7K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$36.6K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$30K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$24.4K |
| 5 |
Jane Street
New York
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$2.74M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.21M |
| 3 |
BlackRock
New York
|
-$72.5K |
| 4 |
BA
Bard Associates
Chicago,
Illinois
|
-$44K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$34K |
DMK Hedge Fund Activity: Q2 2020 in Review
47 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2020, worth a combined $2.74M — down 53% from $5.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new DMK positions and 7 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $41.7K. The largest seller was Anson Funds Management, exiting entirely with an estimated $2.74M sold.
- 47 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $2.74M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2020, down 53% quarter-over-quarter.
- 8 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2020 and 7 closed out, a net change of +1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2020 was Qube Research & Technologies (QRT), an estimated $41.7K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2020 was Anson Funds Management, an estimated $2.74M sold.
Based on aggregated 13F filings for Q2 2020.